恒瑞医药(01276.HK)富马酸泰吉利定注射液获药物临床试验批准

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of Fumaric Acid Tegilide Injection, which will be conducted soon [1] Group 1: Drug Information - Drug Name: Fumaric Acid Tegilide Injection [1] - Dosage Form: Injection [1] - Application Matter: Clinical Trial [1] - Acceptance Numbers: CXHL2500912, CXHL2500913 [1] Group 2: Approval Details - Approval Conclusion: The clinical trial application for Fumaric Acid Tegilide Injection, accepted on August 28, 2025, meets the requirements for drug registration [1] - Purpose of Clinical Trial: To conduct clinical trials for pain relief in mechanically ventilated patients in intensive care [1]